2024
May we actually help clinicians select the best systemic treatment for patients with intermediate‐stage hepatocellular carcinoma?
Giannini E, Strazzabosco M. May we actually help clinicians select the best systemic treatment for patients with intermediate‐stage hepatocellular carcinoma? Liver International 2024, 44: 272-274. PMID: 38289589, DOI: 10.1111/liv.15781.Peer-Reviewed Original ResearchEuropean Society for Organ Transplantation (ESOT) Consensus Statement on Outcome Measures in Liver Transplantation According to Value-Based Health Care
Carbone M, Neuberger J, Rowe I, Polak W, Forsberg A, Fondevila C, Mantovani L, Nardi A, Colli A, Rockell K, Schick L, Cristoferi L, Oniscu G, Strazzabosco M, Cillo U. European Society for Organ Transplantation (ESOT) Consensus Statement on Outcome Measures in Liver Transplantation According to Value-Based Health Care. Transplant International 2024, 36: 12190. PMID: 38332850, PMCID: PMC10850237, DOI: 10.3389/ti.2023.12190.Peer-Reviewed Original ResearchConceptsValue-based health careOutcome measuresEuropean Society of Organ TransplantationLiver transplantationDevelopment of outcome measuresConsensus statementOrgan transplantationValue-basedPatient-focusedAdvanced liver diseaseHealth careMultidisciplinary teamLiver diseaseTransplantationLife-savingEuropean Society for Organ TransplantationPatients
2023
Cell-matrix interactions control biliary organoid polarity, architecture, and differentiation
Fiorotto R, Mariotti V, Taleb S, Zehra S, Nguyen M, Amenduni M, Strazzabosco M. Cell-matrix interactions control biliary organoid polarity, architecture, and differentiation. Hepatology Communications 2023, 7: e0094. PMID: 36972396, PMCID: PMC10503667, DOI: 10.1097/hc9.0000000000000094.Peer-Reviewed Original ResearchConceptsBiliary organoidsNovel organoid modelImmune cell typesOrganotypic culture systemProinflammatory chemokinesStem cell featuresBiliary epitheliumExtracellular matrixEpithelial permeabilityImportant causeBile acidsBiliary differentiationBile transportHuman liverOrganoid modelsDisease modelsCholangiopathyCell featuresTight junctionsLiverCell typesInternal lumenOrganoidsSingle-cell transcriptomicsPathogenic bacteriaIntrahepatic Cholangiocarcinoma Developing in Patients with Metabolic Syndrome Is Characterized by Osteopontin Overexpression in the Tumor Stroma
Cadamuro M, Sarcognato S, Camerotto R, Girardi N, Lasagni A, Zanus G, Cillo U, Gringeri E, Morana G, Strazzabosco M, Campello E, Simioni P, Guido M, Fabris L. Intrahepatic Cholangiocarcinoma Developing in Patients with Metabolic Syndrome Is Characterized by Osteopontin Overexpression in the Tumor Stroma. International Journal Of Molecular Sciences 2023, 24: 4748. PMID: 36902188, PMCID: PMC10003180, DOI: 10.3390/ijms24054748.Peer-Reviewed Original ResearchConceptsMetS patientsMetabolic syndromeNon-alcoholic fatty liver disease/non-alcoholic steatohepatitisNon-alcoholic steatohepatitisIntrahepatic cholangiocarcinoma developmentPutative therapeutic targetDeposition of osteopontinCell-like phenotypeBiliary tumorigenesisExtracellular matrix depositionVascular complicationsSurgical resectionIntrahepatic cholangiocarcinomaICCA cellsOverexpression of osteopontinPredictive biomarkersLiver tumorsCommon conditionHuCCT-1Tumor stromaCholangiocarcinoma developmentPeritumoral areaTherapeutic targetBiliary differentiationOsteopontin overexpressionReply: Novel antidiabetic drugs and the risk for HCC. What else to expect from these “wonderful” drug classes?
Torres M, Jaffe A, Perry R, Marabotto E, Strazzabosco M, Giannini E. Reply: Novel antidiabetic drugs and the risk for HCC. What else to expect from these “wonderful” drug classes? Hepatology 2023, 77: e184-e185. PMID: 36724446, DOI: 10.1097/hep.0000000000000312.Commentaries, Editorials and Letters
2022
Alternative HCC prognostic biomarkers and use of artificial intelligence in the management of HCC
Jaffe A, Taddei T, Giannini E, Ilagan‐Ying Y, Colombo M, Strazzabosco M. Alternative HCC prognostic biomarkers and use of artificial intelligence in the management of HCC. Liver International 2022, 43: 258-259. PMID: 36426717, DOI: 10.1111/liv.15482.Peer-Reviewed Original ResearchDiabetes medications and risk of HCC
Torres M, Jaffe A, Perry R, Marabotto E, Strazzabosco M, Giannini EG. Diabetes medications and risk of HCC. Hepatology 2022, 76: 1880-1897. PMID: 35239194, PMCID: PMC9790535, DOI: 10.1002/hep.32439.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsType 2 diabetes mellitusLiver diseaseRisk of HCCDiabetic medicationsDiabetes mellitusGlucagon-like peptide-1 receptor agonistsSodium-glucose cotransporter 2 inhibitorsGlucose cotransporter 2 inhibitorsPeptide-1 receptor agonistsCotransporter 2 inhibitorsAchievement of euglycemiaInsulin-sensitizing activityLiver cancer tumorigenesisDiabetes medicationsDrug armamentariumInsulin resistanceReceptor agonistRisk factorsInsulin secretionCurrent evidenceNew agentsCancer tumorigenesisGlucose absorptionEndocrinology perspectiveHepatic carcinogenesisESOT Consensus Platform for Organ Transplantation: Setting the Stage for a Rigorous, Regularly Updated Development Process
Cillo U, Weissenbacher A, Pengel L, Jochmans I, Roppolo D, Amarelli C, Belli L, Berenguer M, De Vries A, Ferrer J, Friedewald J, Furian L, Greenwood S, Monbaliu D, Nadalin S, Neyrinck A, Strazzabosco M, Toso C, Zaza G, Thuraisingham R, Berney T, Potena L, Montserrat N, Selzner N. ESOT Consensus Platform for Organ Transplantation: Setting the Stage for a Rigorous, Regularly Updated Development Process. Transplant International 2022, 35: 10915. PMID: 36406781, PMCID: PMC9667481, DOI: 10.3389/ti.2022.10915.Peer-Reviewed Original ResearchConceptsFirst consensus conferenceConsensus statementOrgan transplantationTransplant InternationalConsensus conferenceClinical practiceTransplantation fieldDevelopment of guidelinesTransplantationEuropean SocietyIndependent juryExpert opinionLiterature reviewFinal evidenceEvidenceGuidelinesReviewRecommendationsDepth evidenceLocoregional Therapy in the Management of Intrahepatic Cholangiocarcinoma: Is There Sufficient Evidence to Guide Current Clinical Practice?
Wang Y, Strazzabosco M, Madoff DC. Locoregional Therapy in the Management of Intrahepatic Cholangiocarcinoma: Is There Sufficient Evidence to Guide Current Clinical Practice? Current Oncology Reports 2022, 24: 1741-1750. PMID: 36255606, PMCID: PMC10878124, DOI: 10.1007/s11912-022-01338-5.Peer-Reviewed Original ResearchConceptsLocoregional therapyIntrahepatic cholangiocarcinomaManagement of ICCFuture prospective randomized studiesComparable survival outcomesSafety of hepatectomyProspective Randomized StudyLocal tumor controlNon-surgical approachCurrent clinical practicePurpose of reviewUnresectable diseaseSurgical candidatesSystemic therapyVenous embolizationRandomized studyTransarterial embolizationDismal prognosisMultimodal treatmentSafety profileSurvival outcomesAblative therapyTumor controlPreoperative hypertrophyLiver lobeHolistic management of hepatocellular carcinoma: The hepatologist's comprehensive playbook
Jaffe A, Taddei TH, Giannini EG, Ilagan‐Ying Y, Colombo M, Strazzabosco M. Holistic management of hepatocellular carcinoma: The hepatologist's comprehensive playbook. Liver International 2022, 42: 2607-2619. PMID: 36161463, PMCID: PMC10878125, DOI: 10.1111/liv.15432.Peer-Reviewed Original ResearchConceptsLiver diseaseHepatocellular carcinomaLiver functionRisk factorsRelevant prognostic roleChronic hepatitis BResidual liver functionChronic liver diseaseManagement of patientsCare of patientsCommon risk factorsAppropriate surveillance strategiesSuccessful cancer treatmentC infectionCommon complicationHepatitis BMetabolic syndromePrognostic roleSignificant morbidityLongitudinal careCurrent careCancer recurrenceHCC managementLiver cancerHCC treatmentImmune checkpoint inhibitors in malignancies after liver transplantation: A systematic review and pooled analysis
Kayali S, Pasta A, Torres M, Jaffe A, Strazzabosco M, Marenco S, Giannini EG. Immune checkpoint inhibitors in malignancies after liver transplantation: A systematic review and pooled analysis. Liver International 2022, 43: 8-17. PMID: 36102312, PMCID: PMC10087158, DOI: 10.1111/liv.15419.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsLiver transplant recipientsGraft rejectionOverall survivalICI therapyCheckpoint inhibitorsICI treatmentPooled analysisSystematic reviewDe novo malignanciesAcute graft rejectionDisease control rateRecurrent hepatocellular carcinomaShorter overall survivalGraft lossNovo malignanciesLiver transplantationLT recipientsTransplant recipientsAdvanced malignanciesProspective studyControl rateCase reportHepatocellular carcinomaPatientsOptimization of the BCLC Staging System for Locoregional Therapy for Hepatocellular Carcinoma by Using Quantitative Tumor Burden Imaging Biomarkers at MRI.
Borde T, Nezami N, Laage Gaupp F, Savic LJ, Taddei T, Jaffe A, Strazzabosco M, Lin M, Duran R, Georgiades C, Hong K, Chapiro J. Optimization of the BCLC Staging System for Locoregional Therapy for Hepatocellular Carcinoma by Using Quantitative Tumor Burden Imaging Biomarkers at MRI. Radiology 2022, 304: 228-237. PMID: 35412368, PMCID: PMC9270683, DOI: 10.1148/radiol.212426.Peer-Reviewed Original ResearchConceptsMedian overall survivalAdvanced-stage hepatocellular carcinomaTransarterial chemoembolizationHepatocellular carcinomaBCLC BBCLC COverall survivalTumor burdenBarcelona Clinic Liver Cancer (BCLC) staging systemLiver Cancer staging systemCancer (AJCC) staging systemConventional transarterial chemoembolizationDrug-eluting beadsAllocation of patientsContrast-enhanced MRIBackground PatientsSurvival benefitRetrospective studyStaging systemC tumorsTumor volumePatientsHeterogeneous patientsMonthsChemoembolizationBile acids and their receptors: modulators and therapeutic targets in liver inflammation
Bertolini A, Fiorotto R, Strazzabosco M. Bile acids and their receptors: modulators and therapeutic targets in liver inflammation. Seminars In Immunopathology 2022, 44: 547-564. PMID: 35415765, PMCID: PMC9256560, DOI: 10.1007/s00281-022-00935-7.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsBile acidsLiver diseaseTherapeutic targetAutoimmune liver diseaseCholestatic liver diseaseBile acid receptorAbsorption of lipidsFat-soluble vitaminsLiver inflammationInflammatory diseasesImmunomodulatory propertiesAcid receptorsInflammationDiseaseReceptorsClinical applicationLiverNutrient metabolismPathwayInflammatory pathways and cholangiocarcioma risk mechanisms and prevention
Cadamuro M, Strazzabosco M. Inflammatory pathways and cholangiocarcioma risk mechanisms and prevention. Advances In Cancer Research 2022, 156: 39-73. PMID: 35961707, PMCID: PMC10916841, DOI: 10.1016/bs.acr.2022.02.001.Peer-Reviewed Original ResearchConceptsDevelopment of cholangiocarcinomaNonalcoholic fatty liver diseaseAdequate therapeutic treatmentPrimary sclerosing cholangitisFatty liver diseasePro-inflammatory mechanismsMain risk factorsProdromal diseaseSclerosing cholangitisCaroli's diseaseMetabolic syndromeChronic cholangiopathiesLiver diseasePoor prognosisInflammatory pathwaysBiliary treeCCA developmentRisk factorsImmune responseImmunological responseTherapeutic targetCholangiocarcinomaFluke infestationRole of cellExtrahepatic areasAdjusting Barcelona Clinic Liver Cancer Staging System to the Evolving Landscape of Hepatocellular Carcinoma: A Look to the Future
Strazzabosco M, Cabibbo G, Colombo M. Adjusting Barcelona Clinic Liver Cancer Staging System to the Evolving Landscape of Hepatocellular Carcinoma: A Look to the Future. Gastroenterology 2022, 162: 2106-2108. PMID: 35122767, DOI: 10.1053/j.gastro.2022.01.035.Peer-Reviewed Original Research
2021
Improved performance and consistency of deep learning 3D liver segmentation with heterogeneous cancer stages in magnetic resonance imaging
Gross M, Spektor M, Jaffe A, Kucukkaya AS, Iseke S, Haider SP, Strazzabosco M, Chapiro J, Onofrey JA. Improved performance and consistency of deep learning 3D liver segmentation with heterogeneous cancer stages in magnetic resonance imaging. PLOS ONE 2021, 16: e0260630. PMID: 34852007, PMCID: PMC8635384, DOI: 10.1371/journal.pone.0260630.Peer-Reviewed Original ResearchThe Neglected Role of Bile Duct Epithelial Cells in NASH
Cadamuro M, Lasagni A, Sarcognato S, Guido M, Fabris R, Strazzabosco M, Strain AJ, Simioni P, Villa E, Fabris L. The Neglected Role of Bile Duct Epithelial Cells in NASH. Seminars In Liver Disease 2021, 42: 034-047. PMID: 34794182, DOI: 10.1055/s-0041-1739455.Peer-Reviewed Original ResearchConceptsNonalcoholic fatty liver diseaseNonalcoholic steatohepatitisLiver diseaseInsulin resistancePrevalent liver diseaseBile duct epithelial cellsFatty liver diseaseSubset of patientsCommon pathogenetic mechanismDuct epithelial cellsMultiple biological effectsFibro-inflammationHepatic manifestationNAFLD patientsPortal fibrosisMetabolic syndromeBile ductDuctular reactionDisease progressionPathogenetic mechanismsLiver cancerMetabolic alterationsProgenitor cell compartmentEpithelial cellsDiseaseAn international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs
Cordell H, Fryett J, Ueno K, Darlay R, Aiba Y, Hitomi Y, Kawashima M, Nishida N, Khor S, Gervais O, Kawai Y, Nagasaki M, Tokunaga K, Tang R, Shi Y, Li Z, Juran B, Atkinson E, Gerussi A, Carbone M, Asselta R, Cheung A, de Andrade M, Baras A, Horowitz J, Ferreira M, Sun D, Jones D, Flack S, Spicer A, Mulcahy V, Byan J, Han Y, Sandford R, Lazaridis K, Amos C, Hirschfield G, Seldin M, Invernizzi P, Siminovitch K, Ma X, Nakamura M, Mells G, Consortia P, Consortium C, Siminovitch K, Mason A, Vincent C, Xie G, Zhang J, Consortium C, Tang R, Ma X, Li Z, Shi Y, Group I, Affronti A, Almasio P, Alvaro D, Andreone P, Andriulli A, Azzaroli F, Battezzati P, Benedetti A, Bragazzi M, Brunetto M, Bruno S, Calvaruso V, Cardinale V, Casella G, Cazzagon N, Ciaccio A, Coco B, Colli A, Colloredo G, Colombo M, Colombo S, Cristoferi L, Cursaro C, Crocè L, Crosignani A, D’Amato D, Donato F, Elia G, Fabris L, Fagiuoli S, Ferrari C, Floreani A, Galli A, Giannini E, Grattagliano I, Lampertico P, Lleo A, Malinverno F, Mancuso C, Marra F, Marzioni M, Massironi S, Mattalia A, Miele L, Milani C, Morini L, Morisco F, Muratori L, Muratori P, Niro G, O’Donnell S, Picciotto A, Portincasa P, Rigamonti C, Ronca V, Rosina F, Spinzi G, Strazzabosco M, Tarocchi M, Tiribelli C, Toniutto P, Valenti L, Vinci M, Zuin M, Consortium J, Nakamura H, Abiru S, Nagaoka S, Komori A, Yatsuhashi H, Ishibashi H, Ito M, Migita K, Ohira H, Katsushima S, Naganuma A, Sugi K, Komatsu T, Mannami T, Matsushita K, Yoshizawa K, Makita F, Nikami T, Nishimura H, Kouno H, Kouno H, Ota H, Komura T, Nakamura Y, Shimada M, Hirashima N, Komeda T, Ario K, Nakamuta M, Yamashita T, Furuta K, Kikuchi M, Naeshiro N, Takahashi H, Mano Y, Tsunematsu S, Yabuuchi I, Shimada Y, Yamauchi K, Sugimoto R, Sakai H, Mita E, Koda M, Tsuruta S, Kamitsukasa H, Sato T, Masaki N, Kobata T, Fukushima N, Ohara Y, Muro T, Takesaki E, Takaki H, Yamamoto T, Kato M, Nagaoki Y, Hayashi S, Ishida J, Watanabe Y, Kobayashi M, Koga M, Saoshiro T, Yagura M, Hirata K, Tanaka A, Takikawa H, Zeniya M, Abe M, Onji M, Kaneko S, Honda M, Arai K, Arinaga-Hino T, Hashimoto E, Taniai M, Umemura T, Joshita S, Nakao K, Ichikawa T, Shibata H, Yamagiwa S, Seike M, Honda K, Sakisaka S, Takeyama Y, Harada M, Senju M, Yokosuka O, Kanda T, Ueno Y, Kikuchi K, Ebinuma H, Himoto T, Yasunami M, Murata K, Mizokami M, Kawata K, Shimoda S, Miyake Y, Takaki A, Yamamoto K, Hirano K, Ichida T, Ido A, Tsubouchi H, Chayama K, Harada K, Nakanuma Y, Maehara Y, Taketomi A, Shirabe K, Soejima Y, Mori A, Yagi S, Uemoto S, Egawa H, Tanaka T, Yamashiki N, Tamura S, Sugawara Y, Kokudo N, Consortium P, Atkinson E, de Andrade M, Chalasani N, Luketic V, Odin J, Chopra K, Baras A, Horowitz J, Abecasis G, Cantor M, Coppola G, Economides A, Lotta L, Overton J, Reid J, Shuldiner A, Beechert C, Forsythe C, Fuller E, Gu Z, Lattari M, Lopez A, Schleicher T, Padilla M, Toledo K, Widom L, Wolf S, Pradhan M, Manoochehri K, Ulloa R, Bai X, Balasubramanian S, Barnard L, Blumenfeld A, Eom G, Habegger L, Hawes A, Khalid S, Maxwell E, Salerno W, Staples J, Jones M, Mitnaul L, Consortium U, Sturgess R, Healey C, Yeoman A, Gunasekera A, Kooner P, Kapur K, Sathyanarayana V, Kallis Y, Subhani J, Harvey R, McCorry R, Rooney P, Ramanaden D, Evans R, Mathialahan T, Gasem J, Shorrock C, Bhalme M, Southern P, Tibble J, Gorard D, Jones S, Mells G, Mulcahy V, Srivastava B, Foxton M, Collins C, Elphick D, Karmo M, Porras-Perez F, Mendall M, Yapp T, Patel M, Ede R, Sayer J, Jupp J, Fisher N, Carter M, Koss K, Shah J, Piotrowicz A, Scott G, Grimley C, Gooding I, Williams S, Tidbury J, Lim G, Cheent K, Levi S, Mansour D, Beckley M, Hollywood C, Wong T, Marley R, Ramage J, Gordon H, Ridpath J, Ngatchu T, Grover V, Shidrawi R, Abouda G, Corless L, Narain M, Rees I, Brown A, Taylor-Robinson S, Wilkins J, Grellier L, Banim P, Das D, Heneghan M, Curtis H, Matthews H, Mohammed F, Aldersley M, Srirajaskanthan R, Walker G, McNair A, Sharif A, Sen S, Bird G, Prince M, Prasad G, Kitchen P, Barnardo A, Oza C, Sivaramakrishnan N, Gupta P, Shah A, Evans C, Saha S, Pollock K, Bramley P, Mukhopadhya A, Barclay S, McDonald N, Bathgate A, Palmer K, Dillon J, Rushbrook S, Przemioslo R, McDonald C, Millar A, Tai C, Mitchell S, Metcalf J, Shaukat S, Ninkovic M, Shmueli U, Davis A, Naqvi A, Lee T, Ryder S, Collier J, Klass H, Cramp M, Sharer N, Aspinall R, Ghosh D, Douds A, Booth J, Williams E, Hussaini H, Christie J, Mann S, Thorburn D, Marshall A, Patanwala I, Ala A, Maltby J, Matthew R, Corbett C, Vyas S, Singhal S, Gleeson D, Misra S, Butterworth J, George K, Harding T, Douglass A, Mitchison H, Panter S, Shearman J, Bray G, Roberts M, Butcher G, Forton D, Mahmood Z, Cowan M, Das D, Ch’ng C, Rahman M, Whatley G, Wesley E, Mandal A, Jain S, Pereira S, Wright M, Trivedi P, Gordon F, Unitt E, Palejwala A, Austin A, Vemala V, Grant A, Higham A, Brind A, Mathew R, Cox M, Ramakrishnan S, King A, Whalley S, Fraser J, Thomson S, Bell A, Wong V, Kia R, Gee I, Keld R, Ransford R, Gotto J, Millson C. An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs. Journal Of Hepatology 2021, 75: 572-581. PMID: 34033851, PMCID: PMC8811537, DOI: 10.1016/j.jhep.2021.04.055.Peer-Reviewed Original ResearchConceptsChronic liver diseaseBiliary cholangitisLiver diseaseSmall intrahepatic bile ductsTreatment of PBCPrimary biliary cholangitisIntrahepatic bile ductsAdditional risk lociRisk lociPattern recognition receptorsLicensed medicationsT helperAutoimmune destructionEast Asian cohortsAutoimmune disordersBile ductAsian cohortEuropean cohortInadequate responseNovel therapiesDrug efficacy screeningHealthy individualsGenome-wide association studiesNumerous risk lociRecognition receptorsLiver injury in COVID-19 and IL-6 trans-signaling-induced endotheliopathy
McConnell MJ, Kawaguchi N, Kondo R, Sonzogni A, Licini L, Valle C, Bonaffini PA, Sironi S, Alessio MG, Previtali G, Seghezzi M, Zhang X, Lee A, Pine AB, Chun HJ, Zhang X, Fernandez-Hernando C, Qing H, Wang A, Price C, Sun Z, Utsumi T, Hwa J, Strazzabosco M, Iwakiri Y. Liver injury in COVID-19 and IL-6 trans-signaling-induced endotheliopathy. Journal Of Hepatology 2021, 75: 647-658. PMID: 33991637, PMCID: PMC8285256, DOI: 10.1016/j.jhep.2021.04.050.Peer-Reviewed Original ResearchConceptsLiver sinusoidal endothelial cellsLiver injuryInterleukin-6Sinusoidal endothelial cellsAlanine aminotransferaseLiver histologyD-dimerCOVID-19Primary human liver sinusoidal endothelial cellsSARS-CoV-2 infectionHuman liver sinusoidal endothelial cellsEndothelial cellsSoluble glycoprotein 130IL-6 levelsSmall-interfering RNA knockdownJAK inhibitor ruxolitinibFactor VIII activityProinflammatory factorsInflammatory signalsLarge cohortInhibitor ruxolitinibVWF antigenEndotheliopathyPatientsInjuryX Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis
Asselta R, Paraboschi E, Gerussi A, Cordell H, Mells G, Sandford R, Jones D, Nakamura M, Ueno K, Hitomi Y, Kawashima M, Nishida N, Tokunaga K, Nagasaki M, Tanaka A, Tang R, Li Z, Shi Y, Liu X, Xiong M, Hirschfield G, Siminovitch K, Consortium C, Walker E, Xie G, Mason A, Myers R, Peltekian K, Ghent C, Atkinson E, Juran B, Lazaridis K, Lu Y, Gu X, Jing K, Amos C, Group I, Affronti A, Brunetto M, Coco B, Spinzi G, Elia G, Ferrari C, Lleo A, Muratori L, Muratori P, Portincasa P, Colli A, Bruno S, Colloredo G, Azzaroli F, Andreone P, Bragazzi M, Alvaro D, Cardinale V, Cazzagon N, Rigamonti C, Floreani A, Rosina F, Ciaccio A, Cristoferi L, D’Amato D, Malinverno F, Mancuso C, Massironi S, Milani C, O’Donnell S, Ronca V, Barisani D, Lampertico P, Donato F, Fagiuoli S, Almasio P, Giannini E, Cursaro C, Colombo M, Valenti L, Miele L, Andriulli A, Niro G, Grattagliano I, Morini L, Casella G, Vinci M, Battezzati P, Crosignani A, Zuin M, Mattalia A, Calvaruso V, Colombo S, Benedetti A, Marzioni M, Galli A, Marra F, Tarocchi M, Picciotto A, Morisco F, Fabris L, Crocè L, Tiribelli C, Toniutto P, Strazzabosco M, Consortium U, Ch’ng C, Rahman M, Yapp T, Sturgess R, Healey C, Czajkowski M, Gunasekera A, Gyawali P, Premchand P, Kapur K, Marley R, Foster G, Watson A, Dias A, Subhani J, Harvey R, McCorry R, Ramanaden D, Gasem J, Evans R, Mathialahan T, Shorrock C, Lipscomb G, Southern P, Tibble J, Gorard D, Palegwala A, Jones S, Dawwas M, Alexander G, Dolwani S, Prince M, Foxton M, Elphick D, Mitchison H, Gooding I, Karmo M, Saksena S, Mendall M, Patel M, Ede R, Austin A, Sayer J, Hankey L, Hovell C, Fisher N, Carter M, Koss K, Piotrowicz A, Grimley C, Neal D, Lim G, Levi S, Ala A, Broad A, Saeed A, Wood G, Brown J, Wilkinson M, Gordon H, Ramage J, Ridpath J, Ngatchu T, Grover B, Shaukat S, Shidrawi R, Abouda G, Ali F, Rees I, Salam I, Narain M, Brown A, Taylor-Robinson S, Williams S, Grellier L, Banim P, Das D, Chilton A, Heneghan M, Curtis H, Gess M, Drake I, Aldersley M, Davies M, Jones R, McNair A, Srirajaskanthan R, Pitcher M, Sen S, Bird G, Barnardo A, Kitchen P, Yoong K, Chirag O, Sivaramakrishnan N, MacFaul G, Jones D, Shah A, Evans C, Saha S, Pollock K, Bramley P, Mukhopadhya A, Fraser A, Mills P, Shallcross C, Campbell S, Bathgate A, Shepherd A, Dillon J, Rushbrook S, Przemioslo R, Macdonald C, Metcalf J, Shmueli U, Davis A, Naqvi A, Lee T, Ryder S, Collier J, Klass H, Ninkovic M, Cramp M, Sharer N, Aspinall R, Goggin P, Ghosh D, Douds A, Hoeroldt B, Booth J, Williams E, Hussaini H, Stableforth W, Ayres R, Thorburn D, Marshall E, Burroughs A, Mann S, Lombard M, Richardson P, Patanwala I, Maltby J, Brookes M, Mathew R, Vyas S, Singhal S, Gleeson D, Misra S, Butterworth J, George K, Harding T, Douglass A, Panter S, Shearman J, Bray G, Butcher G, Forton D, Mclindon J, Cowan M, Whatley G, Mandal A, Gupta H, Sanghi P, Jain S, Pereira S, Prasad G, Watts G, Wright M, Neuberger J, Gordon F, Unitt E, Grant A, Delahooke T, Higham A, Brind A, Cox M, Ramakrishnan S, King A, Collins C, Whalley S, Li A, Fraser J, Bell A, Wong V, Singhal A, Gee I, Ang Y, Ransford R, Gotto J, Millson C, Bowles J, Thomas C, Harrison M, Galaska R, Kendall J, Whiteman J, Lawlor C, Gray C, Elliott K, Mulvaney-Jones C, Hobson L, Van Duyvenvoorde G, Loftus A, Seward K, Penn R, Maiden J, Damant R, Hails J, Cloudsdale R, Silvestre V, Glenn S, Dungca E, Wheatley N, Doyle H, Kent M, Hamilton C, Braim D, Wooldridge H, Abrahams R, Paton A, Lancaster N, Gibbins A, Hogben K, Desousa P, Muscariu F, Musselwhite J, McKay A, Tan L, Foale C, Brighton J, Flahive K, Nambela E, Townshend P, Ford C, Holder S, Palmer C, Featherstone J, Nasseri M, Sadeghian J, Williams B, Thomas C, Rolls S, Hynes A, Duggan C, Jones S, Crossey M, Stansfield G, MacNicol C, Wilkins J, Wilhelmsen E, Raymode P, Lee H, Durant E, Bishop R, Ncube N, Tripoli S, Casey R, Cowley C, Miller R, Houghton K, Ducker S, Wright F, Bird B, Baxter G, Keggans J, Hughes M, Grieve E, Young K, Williams D, Ocker K, Hines F, Martin K, Innes C, Valliani T, Fairlamb H, Thornthwaite S, Eastick A, Tanqueray E, Morrison J, Holbrook B, Browning J, Walker K, Congreave S, Verheyden J, Slininger S, Stafford L, O’Donnell D, Ainsworth M, Lord S, Kent L, March L, Dickson C, Simpson D, Longhurst B, Hayes M, Shpuza E, White N, Besley S, Pearson S, Wright A, Jones L, Gunter E, Dewhurst H, Fouracres A, Farrington L, Graves L, Marriott S, Leoni M, Tyrer D, Martin K, Dali-kemmery L, Lambourne V, Green M, Sirdefield D, Amor K, Colley J, Shinder B, Jones J, Mills M, Carnahan M, Taylor N, Boulton K, Tregonning J, Brown C, Clifford G, Archer E, Hamilton M, Curtis J, Shewan T, Walsh S, Warner K, Netherton K, Mupudzi M, Gunson B, Gitahi J, Gocher D, Batham S, Pateman H, Desmennu S, Conder J, Clement D, Gallagher S, Orpe J, Chan P, Currie L, O’Donohoe L, Oblak M, Morgan L, Quinn M, Amey I, Baird Y, Cotterill D, Cumlat L, Winter L, Greer S, Spurdle K, Allison J, Dyer S, Sweeting H, Kordula J, Consortium J, Aiba Y, Nakamura H, Abiru S, Nagaoka S, Komori A, Yatsuhashi H, Ishibashi H, Ito M, Kawai Y, Kohn S, Gervais O, Migita K, Katsushima S, Naganuma A, Sugi K, Komatsu T, Mannami T, Matsushita K, Yoshizawa K, Makita F, Nikami T, Nishimura H, Kouno H, Kouno H, Ota H, Komura T, Nakamura Y, Shimada M, Hirashima N, Komeda T, Ario K, Nakamuta M, Yamashita T, Furuta K, Kikuchi M, Naeshiro N, Takahashi H, Mano Y, Tsunematsu S, Yabuuchi I, Shimada Y, Yamauchi K, Sugimoto R, Sakai H, Mita E, Koda M, Tsuruta S, Kamitsukasa H, Sato T, Masaki N, Kobata T, Fukushima N, Higuchi N, Ohara Y, Muro T, Takesaki E, Takaki H, Yamamoto T, Kato M, Nagaoki Y, Hayashi S, Ishida J, Watanabe Y, Kobayashi M, Koga M, Saoshiro T, Yagura M, Hirata K, Takikawa H, Ohira H, Zeniya M, Abe M, Onji M, Kaneko S, Honda M, Arai K, Arinaga-Hino T, Hashimoto E, Taniai M, Umemura T, Joshita S, Nakao K, Ichikawa T, Shibata H, Yamagiwa S, Seike M, Honda K, Sakisaka S, Takeyama Y, Harada M, Senju M, Yokosuka O, Kanda T, Ueno Y, Kikuchi K, Ebinuma H, Himoto T, Yasunami M, Murata K, Mizokami M, Shimoda S, Miyake Y, Takaki A, Yamamoto K, Hirano K, Ichida T, Ido A, Tsubouchi H, Chayama K, Harada K, Nakanuma Y, Maehara Y, Taketomi A, Shirabe K, Soejima Y, Mori A, Yagi S, Uemoto S, Tanaka T, Yamashiki N, Tamura S, Sugawara Y, Kokudo N, Carbone M, Cardamone G, Duga S, Gershwin M, Seldin M, Invernizzi P. X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis. Gastroenterology 2021, 160: 2483-2495.e26. PMID: 33675743, PMCID: PMC8169555, DOI: 10.1053/j.gastro.2021.02.061.Peer-Reviewed Original ResearchMeSH KeywordsAdultAsian PeopleCarrier ProteinsCell LineageChromosomes, Human, XDNA-Binding ProteinsEndopeptidasesFemaleForkhead Transcription FactorsGenetic LociGenetic Predisposition to DiseaseGenome-Wide Association StudyHumansLinkage DisequilibriumLiver Cirrhosis, BiliaryMaleMitochondrial Precursor Protein Import Complex ProteinsMonosaccharide Transport ProteinsOdds RatioPolymorphism, Single NucleotideProtein Serine-Threonine KinasesProto-Oncogene ProteinsShal Potassium ChannelsWhite PeopleConceptsGenome-wide significant lociAssociation studiesSignificant lociX chromosome variantsGenome-wide association studiesWide association studyMarker association analysisLinkage disequilibrium blockGenetic architectureSuggestive signalsChromosome contributionsChromosome variantsLineage specification factorDisequilibrium blockSpecification factorAssociation analysisGenotype dataEast Asian individualsGenesOTUD5LociRNA levelsComplex autoimmune diseaseFirst comprehensive studySuperenhancers